What was the primary driver of Boston Scientific's sales growth in Q1 2003?

The primary driver of sales growth was the strong performance of the Express2 coronary stent system, coupled with increased sales in both the U.S. and international markets. The company also saw growth in its Endosurgery product lines.

What are the key challenges or risks highlighted by Boston Scientific?

Key challenges include the highly competitive and volatile coronary stent market, the impact of competitor product launches, potential delays in regulatory approvals for its TAXUS drug-eluting stent, managing international operations, and ongoing patent litigation with major competitors.

How is Boston Scientific positioning itself for the future, particularly in the drug-eluting stent market?

Boston Scientific views the drug-eluting stent market as a significant growth opportunity. They are making substantial investments in R&D, clinical trials (specifically for the TAXUS program), and expanding their sales and manufacturing capabilities. The company has initiated a limited international launch for its TAXUS stent and anticipates a U.S. launch later in 2003, aiming to be among the early entrants in this market.

What is the status of Boston Scientific's litigation with Johnson & Johnson regarding coronary stents?

There are multiple ongoing patent litigation cases between Boston Scientific and Johnson & Johnson (and its subsidiaries like Cordis). These include allegations of infringement related to Boston Scientific's Express2 stent and Johnson & Johnson's Cypher stent. Hearings for preliminary injunctions are scheduled for July 2003, and these cases are a significant focus for both companies.

BSX 10-Q Quarterly Report Q1 FY2003 — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation (BSX) reported solid financial performance for the first quarter ended March 31, 2003. Net sales increased by 20% to $807 million compared to the prior year, driven by strong growth in the U.S. and internationally. The company saw significant increases in its Cardiovascular and Endosurgery segments, with notable contributions from the Express2 coronary stent. Net income rose to $97 million, or $0.23 per diluted share, up from $82 million, or $0.20 per diluted share, in the first quarter of 2002. Despite a challenging market and ongoing litigation, the company demonstrated operational improvements and strategic investments, particularly in its promising drug-eluting stent technology (TAXUS). Key financial metrics show positive trends, including an increase in gross profit margin to 72.0% from 69.3%, attributed to cost reductions and a favorable product mix. However, the company also reported specific charges, including $13 million for purchased in-process R&D related to the InFlow acquisition and a $7 million charge for an FTC litigation settlement. Cash flow from operations improved significantly, providing resources for strategic initiatives and investments. The company remains focused on its drug-eluting stent strategy, which it views as a major growth opportunity, with planned U.S. launch expected later in 2003.

Key Highlights

1Net sales grew 20% year-over-year to $807 million.
2Net income increased to $97 million, or $0.23 per diluted share.
3Gross profit margin improved to 72.0% due to operational efficiencies and product mix.
4Acquired InFlow Dynamics Inc., a stent technology development company, for approximately $13 million plus contingent payments.
5Initiated limited launch of the TAXUS drug-eluting coronary stent system in Europe and other international markets.
6Cash flow from operating activities increased significantly to $109 million.
7The company is facing significant patent litigation with competitors like Johnson & Johnson and Guidant Corporation.

BOSTON SCIENTIFIC CORP Quarterly Report for Q1 Ended Mar 31, 2003

Summary

Key Highlights

Frequently Asked Questions